ONC

#24
BeOne Medicines Ltd. American Depositary Shares
286.0300 USD
+0.26%
Sector:
Base: USD
Profit Currency: USD
Daily Range
285.8100
287.1600
Year Range
284.4300
385.2200
Daily Change
+0.26%
Monthly Change
-17.35%
6 month change
-9.40%
Year Change
-9.40%
Previous Close
285.3000
Open
287.1600
Bid
286.0300
Ask
286.0330
Low
285.8100
High
287.1600
Volume
26
Open full chart

Financials

Overview Statement Statistics
Quarterly Annual
  • Market Capitalization 405.5344 B
  • Employee 12 K
  • Founded 2010
  • CEO John Vincent OylerJohn Vincent Oyler
  • Website www.beonemedicines.com
  • Headquarter N/A
  • FIGI BBG00B6WF7T5
  • Industry Technology
Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
1 599
Price to sales ratio
83.86

BeOne Medicines Ltd - American Depositary Shares

BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment. Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has locations on six continents, in over 45 countries. BeOne has a large presence in the Chinese market. BeOne Medicines has developed several medicines, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. On 14 November 2024 the company announced its intention to rebrand as BeOne Medicines. BeOne changed its stock ticker to ONC in January 2025 and redomiciled to Basel, Switzerland in May 2025.